Meeting
2022 ASCO Annual Meeting
INT230-6 monotherapy and in combination with ipilimumab (IPI) across a broad spectrum of refractory soft tissue sarcomas (STS) [Intensity IT-01; BMS#CA184-592].
Authors
Matthew Ingham
Columbia University Irving Medical Center, New York, NY
Matthew Ingham , James S Hu , Giles Francis Whalen , Jacob Stephen Thomas , Anthony B. El-Khoueiry , Diana L. Hanna , Anthony J. Olszanski , Christian Frederick Meyer , Nilofer Saba Azad , Luis H. Camacho , Syed Mahmood , Lewis H. Bender , Ian B. Walters , Lillian L. Siu , Albiruni Ryan Abdul Razak
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT03058289
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 11515)
DOI
10.1200/JCO.2022.40.16_suppl.11515
Abstract #
11515
Poster Bd #
420
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Intratumoral INT230-6 (cisplatin, vinblastine, shao) alone or with ipilimumab prolonged survival with favorable safety in adults with refractory sarcomas.
First Author: Christian Frederick Meyer
Poster
2021 ASCO Annual Meeting
Early results of intratumoral INT230-6 alone or in combination with ipilimumab in subjects with advanced sarcomas.
First Author: Matthew Ingham
Poster
2019 ASCO Annual Meeting
Safety profile of INT230-6, a novel intratumoral (IT) formulation, during injections into a variety of refractory deep and superficial tumors with evidence of tumor regression and immune activation.
First Author: Anthony B. El-Khoueiry
Poster
2022 ASCO Annual Meeting
![Effect of intratumoral INT230-6 on tumor necrosis and promotion of a systemic immune response: Results from a multicenter phase 1/2 study of solid tumors with and without pembrolizumab (PEM) [Intensity IT-01; Merck KEYNOTE-A10].](https://d201v5jt9ylckg.cloudfront.net/288/14354/207587/207587_A1412_poster_pv.jpg)
Effect of intratumoral INT230-6 on tumor necrosis and promotion of a systemic immune response: Results from a multicenter phase 1/2 study of solid tumors with and without pembrolizumab (PEM) [Intensity IT-01; Merck KEYNOTE-A10].
First Author: Jacob Stephen Thomas